We came across a bullish thesis on Aldeyra Therapeutics Inc (ALDX) on ValueInvestorsClub by MrStingy. In this article we will summarize the bulls’ thesis on ALDX. Aldeyra Therapeutics shares were trading at $4.15 when this thesis was published, vs. closing price of $5.38 on Aug 29.
A biotechnologist in a white lab coat manipulating genes in a laboratory.
Aldeyra Therapeutics, a biotechnology company specializing in the development of innovative treatments for immune-mediated diseases, stands out in the industry for its focus on RASP (reactive aldehyde species) inhibition. RASP, known for its role in inflammatory processes, is a novel target in treating conditions like dry eye disease (DED) and other immune disorders. The company’s lead product, reproxalap, is an eye drop formulation designed to inhibit RASP, positioning Aldeyra as a potential leader in the DED market, a condition affecting millions globally.
See Also 33 Most Important AI Companies You Should Pay Attention To
Reproxalap’s journey has been marked by significant milestones and challenges. Initially, the drug showed strong promise in clinical trials, particularly in its ability to rapidly alleviate symptoms of DED, a market currently dominated by drugs like Xiidra and Restasis. These existing treatments, however, have limitations, including delayed onset of action and irritation issues, making reproxalap’s near-instantaneous efficacy a compelling alternative.
Despite this promise, Aldeyra faced a setback in November 2023 when the FDA issued a complete response letter (CRL), effectively rejecting the company’s application for reproxalap’s approval. The FDA required additional trials to demonstrate efficacy on DED symptoms, a hurdle that sent Aldeyra’s stock plummeting by 65%. However, the company has since regrouped, outlining a clear path forward that includes conducting a new Phase 3 trial designed to meet the FDA’s criteria. This trial, set in a dry-eye inducing chamber, will focus on ocular discomfort, a key symptom recognized by the FDA. With a robust trial design and strong prior data, the company is optimistic about resubmitting its application later this year.
Adding to the appeal of Aldeyra’s stock is the strategic partnership with AbbVie. In December, post-CRL, AbbVie signed an option agreement with Aldeyra, potentially bringing in significant upfront payments and milestone bonuses upon reproxalap’s approval. This agreement alone, if executed, would cover more than 100% of Aldeyra’s current enterprise value, highlighting the drug’s undervaluation in the market.
Beyond reproxalap, Aldeyra’s pipeline includes promising RASP inhibitors targeting other inflammatory disorders such as psoriasis and asthma, offering additional growth opportunities. With Phase 3 results expected within six months and FDA approval potentially within a year, Aldeyra’s stock presents a compelling investment opportunity in the biotech sector.
ALDX is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held ALDX at the end of the first quarter which was 11 in the previous quarter. While we acknowledge the potential of ALDX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as ALDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and 10 Best of Breed Stocks to Buy For The Third Quarter of 2024 According to Bank of America.
Disclosure: None. This article is originally published at Insider Monkey.
